Skip to main content
. Author manuscript; available in PMC: 2012 Dec 1.
Published in final edited form as: Curr Breast Cancer Rep. 2011 Dec;3(4):205–211. doi: 10.1007/s12609-011-0053-5

Figure 2.

Figure 2

Imaging examples of Pre-treatment 16α–[18F]-flouro-17β-estradiol (FES; left) and fluorodeoxyglucose (FDG; middle) scans and follow-up FDG post-therapy (right). Dashed arrows show normal liver FES uptake. A, Bone metastasis with robust FES and FDG uptake; response at 3 months. B, Bone metastasis (solid arrow) without FES but with FDG uptake; progressive disease at 6 months. (From Linden, HM et al: J Clin Oncol 24(18), 2006:2793–2799 [21]. Reprinted with permission. © 2008 American Society of Clinical Oncology. All rights reserved.)